Earnings Growth and Profitability
Normalized EPS of $0.333 in H1, up 2%; normalized NPAT $229m, up 2%; statutory NPAT $339m reflecting a positive after-tax asset experience of $105m. Group normalized ROE 11.4%, above full‑year target of 10.7% (outperformance 70 bps).
Record Annuity and Life Sales
Total life sales rose 11% to $5.1bn; record annuity sales of $3.8bn (up 32%). Domestic annuity sales up 37% (domestic figure cited as $3.1bn in CEO remarks); offshore reinsurance annuity sales up 13% to $0.7bn. Annuity book growth 7.4% and overall book growth 5.8%.
Strong Capital Position and Rating Upgrade
Life company PCA ratio 1.58x at 31 Dec with $1.7bn of capital above APRA minimum; S&P upgraded CLC and Challenger Limited one notch (CLC to A+, Challenger Limited to A-). Pro‑forma PCA expected to increase ~16 bps to 1.74 on day 1 under new APRA standards (to ~1.82 if spreads at long‑term average).
Shareholder Returns and Capital Management
Interim fully franked dividend increased 7% to $0.155 per share. Board announced an initial on‑market buyback of $150m as a signal of intent to return capital while preserving flexibility for growth.
Balance Sheet and Liquidity Actions
Average investment assets increased ~5%; cash and equivalents increased 27% to $3.3bn ($700m increase) to support shorter‑duration institutional business and provide deployment flexibility. Invested an additional $1.6bn into high-quality fixed income (cash and AAA securities).
Asset Origination and Distribution Momentum
Originations of $5.9bn during H1 including $2.5bn of private credit. In talks regarding a potential minority stake (up to 25%) in Pepper Money to expand origination capability. Third‑party FUM for Challenger Investment Management up at a 38% four‑year CAGR to $3.1bn; Fidante net flows $1.5bn in H1.
Funds Management and Product Innovation
Funds Management normalized NPAT $29m, up 7% driven by higher net fee income and cost efficiencies. Launched LiFTS income notes platform and acquired an equity stake in Fulcrum Asset Management (recognized $12.6bn FUM addition); alternatives now ~15% of Fidante FUM.
Cost Discipline and Efficiency
Total expenses flat at $154m; cost-to-income ratio improved by ~30 bps and outperformed target range (32–34%), recording the lowest half‑year cost-to-income ratio the company has delivered.
Strategic Positioning and Regulatory Opportunity
Management highlighted participation in APRA capital standard reform as materially positive; strategy to become less capital‑intensive over time and shift asset mix toward fixed income to reduce earnings volatility and improve ROE through the cycle.